Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies

▤ Summary

Alturos Therapeutics advanced its lead candidate ALT0135 into IND-enabling studies. The company is developing an orally bioavailable small molecule for neurodegenerative diseases, with a focus on Alzheimer’s-related protein oligomers. The program comes from preclinical drug discovery work previously acquired from Galapagos. Alturos also says it is in a Series A funding round to speed development and move the candidate toward clinical proof-of-concept.

▦ Linked Companies